AutoGenomics Gets FDA Clearance for CYP2C19 Test, But Cannot Mention Plavix PGx | GenomeWeb

By Turna Ray

Although AutoGenomics has garnered clearance from the US Food and Drug Administration for its Infinity CYP2C19 Assay — which gauges the *2, *3, and *17 SNPs in the gene — the test's label makes no mention of its use as a pharmacogenetic test to administer Plavix.

AutoGenomics announced this week that it received 510(k) clearance from the US Food and Drug Administration to market its Infiniti CYP2C19 Assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.